Genetic analysis of intestinal polyp development in Collaborative Cross mice carrying the 
                      mutation by unknown
RESEARCH ARTICLE Open Access
Genetic analysis of intestinal polyp
development in Collaborative Cross mice
carrying the ApcMin/+ mutation
Alexandra Dorman1, Daria Baer1, Ian Tomlinson2, Richard Mott2 and Fuad A. Iraqi1*
Abstract
Background: Colorectal cancer is an abnormal tissue development in the colon or rectum. Most of CRCs develop
due to somatic mutations, while only a small proportion is caused by inherited mutations. Familial adenomatous
polyposis is an inherited genetic disease, which is characterized by colorectal polyps. It is caused by inactivating
mutations in the Adenomatous polyposis coli gene. Mice carrying and non-sense mutation in Adenomatous polyposis
coli gene at site R850, which designated ApcR850X/+ (Min), develop intestinal adenomas, while the bulk of the disease
is in the small intestine. A number of genetic modifier loci of Min have been mapped, but so far most of the underlying
genes have not been identified. In our previous studies, we have shown that Collaborative Cross mice are a powerful
tool for mapping loci responsible for phenotypic variation. As a first step towards identification of novel modifiers of Min,
we assessed the phenotypic variation between 27 F1 crosses between different Collaborative cross mice and
C57BL/6-Min lines.
Results: Here, C57BL/6-Min male mice were mated with females from 27 Collaborative cross lines. F1 offspring
were terminated at 23 weeks old and multiple phenotypes were collected: polyp counts, intestine length, intestine
weight, packed cell volume and spleen weight. Additionally, in eight selected F1 Collaborative cross-C57BL/6-Min lines,
body weight was monitored and compared to control mice carry wildtype Adenomatous polyposis coli gene. We found
significant (p < 0.05) phenotypic variation between the 27 F1 Collaborative cross-C57BL/6-Min lines for all the tested
phenotypes, and sex differences with traits; Colon, body weight and intestine length phenotypes, only. Heritability
calculation showed that these phenotypes are mainly controlled by genetic factors.
Conclusions: Variation in polyp development is controlled, an appreciable extent, by genetic factors segregating
in the Collaborative cross population and suggests that it is suited for identifying modifier genes associated with
ApcMin/+ mutation, after assessing sufficient number of lines for quantitative trait loci analysis.
Keywords: ApcMin/+, Colorectal cancer, Collaborative cross, Familial adenomatous polyposis, Genetic modifier,
Moms, Phenotyping, Recombinant Inbred lines
Background
Genome-wide association studies (GWAS) have identi-
fied numerous common alleles that affect cancer suscep-
tibility [1–4], yet the combined effects of the alleles
currently discovered are too small to explain the bulk of
heritable disease risk. This suggests, that the genetic in-
fluence on cancer susceptibility might not be entirely
due the combined additive effects of individual alleles.
Experimental mouse models of cancer are ideal for
examining the effects of genetic modifiers that act epis-
tatically with known susceptibility loci. Epistasis is diffi-
cult to detect in human GWAS due to the very large
sample size required. However, it is straightforward to
engineer mutant mice in which a known susceptibility
locus is altered to change the risk of disease. By crossing
the mutant onto a population of mice with different gen-
etic backgrounds of naturally occurring variation, it is
theoretically possible to map modifier loci.
The great majority of colorectal cancers (CRCs) develop
from adenomas [5, 6]. Apc mutations are found in the
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germ line of patients with Familial Adenomatous Polyp-
osis (FAP) and in over 80 % of sporadic colorectal aden-
omas [7–11]. Apc is a tumor suppressor gene [7], that
encodes a large protein [8] that regulates Wnt pathway
activity through its interaction with the transcription fac-
tor β-catenin [12–17]. Apc also interacts with numerous
actin and microtubule-associated proteins [17–19]. Roles
for Apc in cell migration have been demonstrated in vitro
and in mouse models [13, 20].
Several mouse models with heterozygous germline
mutations of Apc exist, and all of these develop aden-
omatous intestinal polyps [21, 22]. Different mutations
are associated with different disease severities. For
example, ApcR850X/+ (Min) mice typically develop ~100
intestinal polyps at 3–4 months of age, whereas the
Apc1322T/+ mice develop polyps earlier in life, and the
Apc1638N/+ model produces only a handful of polyps at
over a year of age [21–24]. Like humans with germline
mutations in Apc, Min mice are predisposed to intestinal
adenoma formation, which is influenced by modifier loci
carried by different inbred strains. Assessing Apc modi-
fiers in the mouse is usually quantitative by counting
numbers of intestinal polyps. The Mom1 (modifier of
Min 1) locus was the first Apc modifier to be identified
[21, 25]. It encodes secretory phospholipase A2 (Pla2), a
Paneth cell-specific marker with effects on tumorgenesis
that remain unclear [24, 26]. Another modifier, Mom2, is
an Atp5a1 mutation that acts by suppressing loss of
heterozygosity through cell lethality [14, 27, 28]. Other
Mom loci have been mapped, but no other genes been
cloned [29]. The most comprehensive modifier screen to
date in a population of female BXH recombinant inbred
mice backcrossed to C57BL/6-Min males [29] identified
five modifier loci. Given that the genetic backgrounds of
inbred strains have profound effects on polyp numbers,
further modifiers almost certainly exist. These might
affect not only polyp numbers, but other traits such as
progression to cancer and location in the bowel [30].
The Collaborative Cross (CC) is a panel of recombin-
ant inbred (RI) strains derived from a genetically diverse
set of eight founder strains: A/J, C57BL/6 J, 129S1/SvImJ,
NOD/LtJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ and WSB/EiJ.
It was designed to provide complex trait analysis with
greater power than previous approaches [31, 32]. A full
description of the CC population under development at
Tel-Aviv University is provided in recent publications
[33–40]. The key features of the CC in relation to modifier
mapping are the very large number of variants segregating
in the population (there are over 36 million SNPs) [36],
and the relatively high level of recombination present
compared to other mouse RI sets (4.4 million SNPs segre-
gate between the founders C57BL/6 J and C3H/HeJ of the
BXH mice [41]). Three founders of the CC are wild-
derived strains, representing the three different mice
subspecies: Mus musculus castaneus (CAST/EiJ), Mus
musculus musculus (PWK/PhJ) and Mus musculus domes-
ticus (WSB/EiJ), which contribute many sequence variants
not segregating among classical strains descended from
Mus musculus domesticus [41–43], and account for the
bulk of the variants segregating in the CC. Consequently
mapping of quantitative trait loci (QTLs) using the CC
often identifies QTLs involving contrasts between the
wild-derived strains [37]. By incorporating polymorphisms
data from the genome sequences of the CC founders [36],
and restricting attention to variants whose differences
across the founders are consistent with the pattern of
action of the QTL, candidate genes under QTLs can be
identified [36, 37, 44–47].
As a first step towards mapping modifiers of ApcMin/+
in CC mice, we assessed polyp-related phenotypes dis-
section in F1 hybrids of females from 27 CC lines to
C57BL/6-Min male mice. In this report, we analyze
phenotypic variation and the broad sense heritability
(H2) of these traits.
Materials and Methods
Breeding, genotyping and phenotyping F1 CC-C57BL/6-
Min mice
The C57BL/6-Min and CC mice were provided by the
Small Animal Facility at Sackler Faculty of Medicine, Tel
Aviv University (TAU). The CC lines were between the
11th and 38th generation of inbreeding by full-sib mat-
ing [34, 48]. They were genotyped using the MEGA-
MUGA (60 k SNPs) genotyping array, which showed
that each line was at least 85 % homozygous. Full details
of the development of the CC are given in Iraqi et al.
2008 [34]. All experimental mice and protocols were
approved by the Institutional Animal Care and Use
Committee of TAU (approval numbers: M-08-075; M-
12-024). Institutional Animal Care and Use Committee
of TAU adherers to the Israeli guidelines that follow
NIH/USA animal care and use protocols. Mice were
housed on hardwood chip bedding in open-top cages at
the animal facility and were given tap water and rodent
chow ad libitum. F1-CC-C57BL/6-Min mice were moni-
tored daily for their overall health status. Mice which
lost 10 % of their bodyweight between two measured
points, or over 20 % of their initial bodyweight, or were
observed to be suffering (less movement and activity),
and based on the consultation with the Veterinarian at
the small animal unit, were terminated.
At 4 weeks old, 0.5 cm tail biopsies were collected and
DNA isolated by NaOH boiling method [49]. The F1 mice
were genotyped by PCR for the ApcMin/+ mutant allele,
using primers MAPC-min (TTCTGAGAAAGACAGAA
GTTA), MAPC-15 (TTCCACTTTGGCATAAGG), and
MAPC-9 (GCCATCCCTTCACGT). For Apc wild type
alleles, we used primers MAPC-15 and MAPC-9, which
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amplify 618 bp PCR products, while for the mutant form
we used MAPC-min and MAPC-15, which amplify
317 bp PCR products [50]. For later identification each
mouse was ear-labelled.
After five months the F1-CC-C57BL/6-Min mice were
terminated, their small intestine and colon extracted and
washed with PBS. The small intestine were divided into
three segments (SB1-proximal, SB2-middle and SB3-
distal), and the colon was kept as whole and spread over
3 mm paper. The intestines were fixed in 10 % Neutral
Buffered Formalin (NBF) for overnight, and stained by
0.02 % methylene blue. The samples were then examined
by binuclear. The number and sizes of polyps in each of
the four intestinal sub-regions were recorded as de-
scribed in Rudling et al. 2006 [51]. The total body
weight, weight of spleen, weight and length of intestine
and the total packed cell volume (PCV) were also mea-
sured at the terminal point. Additionally presented num-
ber of polyps per centimeter of intestine, which was
calculated using the follow formula: Number of polyp
per cm = Total number of polyps/Total length of intes-
tine. Spleen weight was normalized to total body weight
using the follow formula: Spleen %Weight = (Spleen
weight (g)/total body weight (g)) × 100. Intestine weight
was normalized to total body weight using the follow
formula: Intestine %Weight = (Intestine weight (g)/total
body weight (g)) × 100. Blood was collected by heart
puncture [52, 53] into hematocrit heparinized capillary
by hematocrit centrifuge CM-70 (ELMI). The % packed
cell volume (%PCV) was calculated based on formula:
(Total plasma (uL) × 100)/total blood volume (uL).
For 40 selected males from 8 F1-CC-C57BL/6 lines
(with representation of control (Apc+/+) and affected
(ApcMin/+) mice) body weight was monitored along the
experiment at 5 time points, at the weaning (8 weeks
old), 12, 16, 19 and 23 weeks old.
Data analysis
Data analysis performed using a statistical software pack-
age SPSS version 19. Analysis of variance (ANOVA) was
performed to test the differences of polyp’s number, intes-
tinal %weight and length, spleen %weight, %PCV between
27 F1 CC-C57BL/6-Min lines, and body weight between
8 F1 CC-C57BL/6 lines. Clustering analysis of total polyps
was performed by Duncan’s test. All the results repre-
sented as Mean ± Standard Error, if n = 1 represented only
the value of the phenotype.
Correlation between traits (polyp number, intestinal
%weight and length, polyps per cm, %PCV and spleen
%weight) was measured by Pearson product-moment
correlation coefficient.
Heritability (H2) was estimated as the proportion of
phenotypic variation explained by differences between




C57BL/6-Min males were crossed to females from 27
CC lines, total progeny of 403 F1 CC-C57BL/6 mice
were generated as detailed in Additional file 1: Table 1S.
We found that 179/403 mice (44.42 %; 91 males and
88 females) were heterozygous for the knockout allele
(carried the ApcMin/+ allele) and therefore were F1 CC-
C57BL/6-Min. The other progeny were wild-type for
the Apc allele, and are henceforth denoted as F1 CC-
C57BL/6. A second set of 40 male mice including 25
carried ApcMin/+ allele and 15 non carrier (control) of
8 CC lines were also generated, separately to study
body weigh differences between these two genotypes.
Body weight monitoring of F1 CC-C57BL/6 lines
A previous study showed that ApcMin/+ mice lose their
body weight during polyp’s development [54, 55]. Here,
body weight performances of males from 8 randomly se-
lected F1 CC-C57BL/6-Min lines was monitored during
the experiment at 5 time points, and compared to the
corresponding F1 CC-C57BL/6 wild type lines, results
presented in Fig. 1.
At the initial time point (8 weeks old) the body weight
of control lines varied between 22.17 g (IL2126) to
28.6 g (IL611) (Fig. 1a). Body weight of ApcMin/+ carriers
varied between 22.45 ± 0.46 g (Mean ± Standard Error)
(IL1912) to 29.6 g (IL557) (Fig. 1b). One-way ANOVA
showed that body weight significantly (p < 0.05) different
between lines, within both controls and ApcMin/+ groups.
In contrast no significant differences were found at the
initial time point between the control and ApcMin/+
groups, within each examined line.
During the experiment ApcMin/+ carriers displayed
three patterns of body weight changes: body weight loss
(marked as - · - · - · - in Fig. 1b), Plateau (—— in Fig. 1b)
and continues body weight accumulation ( in Fig. 1b).
While all the control lines gained weight continuously
during the experiment.
As shown in Fig. 1b, two lines – IL188 and IL611 lost
body weight during the experiment. Table 1 shows delta
body weight between 23 and 8 wks. old, was -0.34 g and
2.39 g, for IL611 and IL188, respectively. Line IL188 car-
ries ApcMin/+ lost -1.15 g of total body weight between
weeks 19 to 23. Over the entire experiment, IL188 mice
carries ApcMin/+ gained weight, but started losing weight,
only late in the study, whereas IL611 lost weight rela-
tive to initial weight. The control mice of same lines
gained 12.18 g (IL611) and 13.4 g (IL188), which were
significantly different from the ApcMin/+ carriers group.
Interestingly, ApcMin/+ carriers from these lines also
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developed high number of polyps, and will be presented
later on.
The ApcMin/+ carriers group of lines IL3438 and
IL3912 (Fig. 1b) exhibited Plateau pattern during the
final weeks of the experiment (after week 20). Table 1
shows that delta body weight for these lines was 9.59 g
(IL3438) and 7.03 g (IL3912). Control mice from the
same lines gained 14.36 g (IL3438), which wasn’t signifi-
cantly different from ApcMin/+ carriers, and 13.28 g
(IL3912) which was significantly different (p < 0.01) com-
pared to ApcMin/+ carriers. Values for the rest tested phe-
notypes of these lines summarized in Table 1.
The remaining lines – IL2126, IL557, IL1912 and
IL4052, which are also presented in Fig. 1b, have demon-
strated continues increase in body weight throughout
the experiment. Line IL2126 has exhibited no significant
difference in weight accumulation tendency between the
experimental (7.33 g) and control groups (8.11 g). Line
IL557 showed significant difference (p < 0.039) in delta
body weight accumulation between the experimental
(8.65 g) and control groups (14.12 g). Line IL1912
showed no significant difference in delta body weight ac-
cumulation between the experimental (14.04 g) and con-
trol groups (17.9 g). Line IL4052 showed no significant
Fig. 1 Body weight (±SE) of the a control and b ApcMin/+ groups at 5 time points (8, 12, 16, 19 and 23 weeks old) of 8 different set of CC lines.
The X-axis represents the time points (in weeks) while the Y-axis represents values of body mass (g). One-way ANOVA performed for statistical
analysis, p < 0.05
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difference in delta body weight accumulation between
the experimental (10.85 g) and control groups (19.51 g).
Values for the rest tested phenotypes summarized in
Table 1.
At the final time point of the experiment (23 wks. old)
lines from both groups, control and ApcMin/+ carriers,
displayed significant differences in their body weight
values. Additionally at this step of the experiment we
found significant variation between control and ApcMin/+
carriers group within each line.
Polyp counts in F1 CC-C57BL/6-Min mice
Mice were terminated at age of 23 weeks and the gastro-
intestinal tract (small intestine and colon) was extracted
for polyps count, results are presented in Fig. 2. Across
the 27 F1 CC-C57BL/6-Min lines mean polyp count was
27.3 ± 1.49. The cohort exhibited a wide range of pheno-
typic variability, from 9 polyps (IL4052) to 69 ± 6.83
(IL3348). One-way ANOVA revealed significant variation
between CC lines (p < 0.01). Polyp counts were approxi-
mately normally distributed, suggesting intervention of nu-
merous genetic factors in this trait. Duncan’s analysis
divided tested lines into 9 clusters, presented by continu-
ous lines under the graph in Fig. 2. Interestingly, mean
polyp count in the parental line C57BL/6-Min was 45.50 ±
5.98, so that the majority (20/27, 74.07 %) of F1 CC-
C57BL/6-Min lines have fewer polyps than the parental
line, despite the fact that the number of defective Apc
alleles is the same in all cases. When we compared the
polyp counts in the male mice of the 8 CC lines assessed
in the second set of lines presented in Fig. 1a and Table 1
and Additional file 1: Table 7S, majority of lines were con-
sistent on both sets. Notably, that SE is very high in many
lines. Based on one way ANOVA, we have found that some
lines are significantly different between male and female,
mice. As for polyp counts, we have found that some lines
are significantly different with this trait between both sexes
as presented in Additional file 1: Table 7S, however, overall
across all the tested lines sex was significant different with
polyp counts.
Next we asked if different segments of the intestine
exhibit differential polyp distribution. The small intestine
was subdivided into 3 parts (small intestine proximal-
SB1, middle-SB2 and distal-SB3), and the colon was
related separately. Polyp counts were recorded in each
region. Figure 3 shows the distribution of polyps in the
four components of gastrointestinal tract in the 27 F1 CC-
C57BL/6-Min lines and C57BL/6-Min. Overall, polyps
were distributed approximately equally between 4 seg-
ments: SB1 with 5.96 ± 0.4 polyps (21.58 %), SB2 with
7.73 ± 8.17 (26.98 %), SB3 with 7.97 ± 7.69 (28.97 %) and
colon with 6.2 ± 3.9 (22.47 %). The percentages of polyp
counts in C57BL/6 J-Min strain were 23.63 % (SB1),
37.91 % (SB2), 26.92 % (SB3) and 11.54 % (colon).
Interestingly some lines showed approximately the
same number of polyps, which were differentially dis-
tributed across the intestine. For example, line IL611
had 55.33 ± 10.91 and line IL188 55.4 ± 13.71 polyps.
However, in IL611 only 3.01 % of polyps were in the
colon; while IL188 had 22.74 % of polyps in the same
segment. Similarly in SB2, IL611 showed 39.16 %
polyps and IL188 22.02 %. This suggests that different
Table 1 Summary of collected phenotypes at 23 weeks old: Total polyps, %PCV, Spleen %Weight and Delta body weight (Body
weight 23 weeks old-Body weight 8 weeks old), for control and ApcMin/+ mice from 8 F1 CC-C57BL/6
CC Line Apc N (mice) Total Polyps %PCV Spleen %Weight Delta Body weight (gr.)
IL611 Min 3 55.33 ± 10.91 25.96 ± 4.32 2.7637 ± 0.677 -0.34
WT 2 0 54.62 ± 0.1 0.1962 ± 0.0007 12.18
IL188 Min 8 70.38 ± 10.78 29.45 ± 3.8 1.9698 ± 0.3419 2.39
WT 3 0 54.93 ± 2.53 0.1762 ± 0.0667 13.4
IL3438 Min 2 67.5 ± 24.5 38.93 ± 6.67 1.2124 ± 0.691 9.59
WT 2 0 53.75 ± 4.55 0.1729 ± 0.024 14.36
IL3912 Min 3 42.33 ± 5.36 35.2 ± 2.29 0.7768 ± 0.1209 7.03
WT 2 0 56.62 ± 4.06 0.1699 ± 0.0496 13.28
IL2126 Min 4 14.75 ± 4.05 51.75 ± 1.54 0.2966 ± 0.0602 7.33
WT 1 0 51.92 0.1651 8.11
IL557 Min 1 53 34.25 1.4379 8.65
WT 3 0 55.6 ± 5.92 0.2656 ± 0.0357 14.12
IL1912 Min 2 43.5 ± 1.5 41.84 ± 1.84 0.5044 ± 0.0786 14.04
WT 1 0 53.75 0.1609 17.9
IL4052 Min 2 9 48.96 ± 5.38 0.3218 ± 0.017 10.85
WT 1 0 60.26 0.1703 19.51
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Fig. 2 Average number of polyps (±SE) in 27 F1 CC-C57BL/6-Min lines (n = 1-16 mice/line). The X-axis represents CC lines, C57BL/6 strain carrying
the ApcMin/+ mutation (first black column) and CC-Mean (black column ~ in the middle), while the Y-axis number of polyps. Continuous lines
under the graph represent 9 clusters based on Duncan’s Least Significant Range (LSR) test. One-way ANOVA performed for statistical
analysis, p < 0.05
Fig. 3 Distribution of all counted polyp in three parts of small intestine: SB1-proximal, SB2-middle, SB3-distal and colon. The X-axis represents CC
lines, C57BL/6 strain carrying the ApcMin/+ mutation (first black column) and CC-Mean (black column ~ in the middle), while the Y-axis number of
polyps. One-way ANOVA performed for statistical analysis, p < 0.05
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genetic factors might be involved in polyp development
throughout the gastrointestinal tract.
Intestine Length
Since tumor development might affect the length and
weight of the intestine, we asked if these phenotypes also
differed across the population. Additional file 1: Figure 1S
(presented in supplementary matherials) shows the distri-
bution of intestine length (cm) across the F1 CC-C57BL/
6-Min lines and the C57BL/6-Min parental strain. The
mean intestine length of the entire population was
47.92 ± 0.28 cm, ranging from 43.52 ± 0.85 cm (IL2126)
to 51.83 ± 1.21 cm (IL3348). One-way ANOVA showed
that intestine length varied significantly (p < 0.01) between
27 F1 CC-C57BL/6-Min lines. The mean intestine length
for the parental strain, C57BL/6-Min, was 48.55 ± 1.55 cm.
Number of polyps per centimeter
Next, number of polyps per cm of intestine was calcu-
lated (as described in Matirials and Methods section),
results presented in Additional file 1: Figure 2S. As for
entire population, avarge number of polyps per cm was
0.5676 ± 0.0291. Lowest value of 0.1877 ± 0.0356 polyps
per cm was recorded for line IL4052, which had overall
only 9 polyps. Highest value of 1.3267 ± 0.0421 polyps
per cm was recorded for line IL3348, which had overall
69 ± 6.836 polyps. The parental line C57BL/6 showed
1.142 ± 0.0297 polyps per cm.
Additionally, histogram plot in Additional file 1: Figure
3S shows frequency of number of lines within different
ranges of polyps per cm values. It was found that majority
of tested CC lines, 9 lines, developed between 0.2721 ±
0.1815 to 0.4143 ± 0.0283 polyps per cm of intestine. As
for extreme cases: one line (IL4052) developed 0.1877 ±
0.0356 polyps per cm, and 2 lines (IL521 and IL3348)
developed more than 1.2209 ± 0.0177 polyps per cm.
Intestine Weight
Additional file 1: Figure 4S shows the distribution of in-
testine %weight. The mean across the entire population
was 2.63 ± 0.71 %, ranging from 1.63 ± 0.16 % (IL2750)
to 4.82 ± 0.71 % (IL611). One-way ANOVA showed that
the intestine %weight varied significantly (p < 0.01) be-
tween tested lines. The mean intestine %weight in C57BL/
6-Min was 4.5 ± 0.08.
Packed Cell Volume
ApcMin/+ mice suffer from severe anemia [56], and severe
anemia is the main cause of death in these mice [57]. In
order to investigate this phenmenon in the F1 CC-
C57BL/6-Min population, the packed cell volume (PCV)
was measured at the terminal point of experiment, re-
sults are summarized in Additional file 1: Figure 5S. The
overall mean of entire population was 44.6 ± 0.7 %, and
individual lines ranged from 25.96 ± 4.32 % (IL611) to
51.94 ± 1.33 % (IL4457). Normal PCV values are in the
range 45-55 % [56], so 51.85 % (14/27) of the CC-
C57BL/6-Min lines were below the normal range. One-
way ANOVA revealed that %PCV varied significantly
(p < 0.01) between F1 CC-C57BL/6-Min lines. The par-
ental C57BL/6-Min line showed the lowest %PCV value
of 24.35 ± 2.13 %. When we compared the %PCV in the
male mice of the 8 CC lines assessed in the second set
of lines presented in Fig. 1a and Table 1, majority of
lines were consistent on both sets. Notably, that SE is
very high in many lines.
Spleen Weight
It has been reported that ApcMin/+ mice suffer from
splenomegaly, (enlargement of the spleen) [58]. Additional
file 1: Figure 6S shows the distribution of spleen %weights.
The mean of the tested 27 F1 CC-C57BL/6-Min lines
was 0.53 ± 0.05 %, ranging from 0.18 ± 0.02 % (IL3738)
to 2.76 ± 0.67 % (IL611). One-way ANOVA showed that
spleen %weight varied significantly (p < 0.01) between
lines. The parental line, C57BL/6-Min, had relatively high
value of 1.52 ± 0.22 %. When we compared the spleen
weight in the male mice of the 8 CC lines assessed in the
second set of lines presented in Fig. 1a and Table 1, major-
ity of lines were consistent on both sets. Notably, that SE
is very high in many lines.
Correlation between phenotypes
Next we were interested to investigate the relationship
between polyp’s development and related phenotypes.
Table 2 shows Pearson correlations between traits across
the 27 F1 CC-C57BL/6-Min lines.
The length of intestine and total number of polyps is
positively correlated (Pearson correlation coefficient
(r) = 0.589, p < 0.01). This suggests that a high number
of polyps are associated with longer intestinal track.
The scatter plot in Fig. 4a (R2 = 0.346) shows data
distribution of these two traits.
Similarly intestine %weight is positively correlated with
total polyps count (r = 0.695, p < 0.01). Suggesting that a
high number of polyps are associated with heavier intes-
tinal track. The scatter plot in Fig. 4b (R2 = 0.484) shows
data distribution of these two traits.
In contrast, a negative correlation (r = -0.841, p < 0.01)
was observed between %PCV and total number of polyps,
i.e. high number of polyps are associated with low values
of %PCV. The scatter plot in Fig. 4c (R2 = 0.707) shows
data distribution of these two traits.
The spleen %weight and total number of polyps were
positively correlated (r = 0.743, p < 0.01). This suggests
that high numbers of polyps are associated with heavier
spleen, indicating splenomegaly. The scatter plot in Fig. 4d
(R2 = 0.553) shows data distribution of these two traits.
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As was expected there is strong positive correlation
was found between %PCV and spleen %weight. Pearson
test showed negative correlation (r = -0.846, p < 0.01) be-
tween these traits, suggesting that anemia accompanied
by splenomegaly.
As was expected there is strong positive correlation be-
tween Total polyps and Polyps per cm (r = 0.998, p < 0.01),
corresponding scatter plot in Fig. 4e (R2 = 0.995).
Additionally significant positive correlations were found
between Polyps per cm and Intestine length (r = 0.539,
p < 0.01), Intestine %Weight (r = 0.714, p < 0.01) and
Spleen %Weight (r = 0.764, p < 0.01), significant negative
correlation was found with %PCV (r = -0.852, p < 0.01).
Heritability
Our last aim of this repost was to determine whether
variation in polyp development and other tested pheno-
types has a genetic basis in F1 CC-C57BL/6-Min popula-
tion. In order to answer this question, heritiabilities (H2)
values were calculated, results summarized in Table 3.
All the phenotypes have high heritability values, mean-
ing that tested traits have strong genetic basis. The high-
est value of 0.641 was found for the phenotype of all
counted polyps in along the gastrointestinal tract (Total
Polyps), while the lowest value of 0.305 was found for
the number of polyps in the colon.
Discussion
This is the first analysis of intestinal polyp’s development
and related traits in 27 F1 CC-C57BL/6 lines carrying the
ApcMin/+ mutation. All the tested phenotypes showed wide
variability, suggesting that the diverse genetic background
of the CC lines is contributes to this variation. Analysis of
heritability confirmed this statement by showing that the
majority of phenotypic variation is due to genetics.
Previous studies have shown that ApcMin/+ mice lose
body weight during disease progression [59], which
mimics the loss of weight observed in cancer patients,
especially of gastrointestinal cancers [60]. In our study, in
eight randomly selected lines, we found that body weight
at the start of experiment showed significant variation
between lines, but there were no significant differences
between knockout and control mice within each line. This
suggests that initially the presence of ApcMin/+ mutation
has no influence on body weight. However, throughout
the experiment we identified 3 different patterns of body
weight performances in ApcMin/+: loss of body weight,
plateau and continuous accumulation of body weight. Re-
sistant lines accumulate their body weight continuously
and do not develop multiple polyps, while susceptible
lines lose body weight, presumably because of the polyp
burden. These results emphasize the importance of gen-
etic background in the response to ApcMin/+ mutation.
Previous studies have shown that genetically diverse
mouse strains, carrying ApcMin/+ mutation, vary in intes-
tinal tumor development [29]. Our results support this
finding. Additionally, we found that polyp counts in F1
CC-C57BL/6-Min lines are distributed below and above
the parental (C57BL/6-Min) mean value. We conclude
that the CC population contains suppressors and en-
hancers genetic elements of the ApcMin/+ mutation.
The different four parts (SB1, SB2, SB3 and colon) of
the gastrointestinal tract have specific physiological func-
tion, due to different gene expression profiles, pH and
microbiota [61]. In a previous study with ApcMin/+ mice it
was reported that the density of polyps varies across the
gastrointestinal tract [23]. Our results confirm this obser-
vation and suggest that tumorgenesis in different parts of
intestine is controlled by different genes. Additionally
current results suggest that high levels of polyp prolifera-
tion in ApcMin/+ mice affect the length and weight of the
intestine. The much polyps mouse have the longer and
heavier the gastrointestinal tract.
Our data also support the findings that ApcMin/+ mice
suffer from anemia [56] as we observed a negative correl-
ation between the number of polyps and %PCV. Suscep-
tible lines with high total polyp counts had low %PCV
values, while resistant lines for polyp development
displayed normal %PCV values.
ApcMin/+ mice also develop splenomegaly [59]. Possible
causes include viral or bacterial infections, cirrhosis,
venous pressure in spleen or liver, metastasis of solid tu-
mors or hemolytic anemia [60]. Our results confirm that
ApcMin/+ mice develop splenomegaly concurrently with
Table 2 Pearson correlation values between traits: total polyps, intestine length, intestine %weight, %PCV, spleen %weight and
polyps per cm
Total Polyps Intestine Length Intestine %Weight %PCV Spleen %Weight Polyps per cm
Total Polyps 1 0.589** 0.695** -0.841** 0.743** 0.998**
Intestine Length 0.589** 1 0.266 -0.457* 0.317 0.539**
Intestine %Weight 0.695** 0.266 1 -0.769** 0.815** 0.714**
%PCV -0.841** -0.457* -0.769** 1 -0.846** -0.852**
Spleen %Weight 0.743** 0.317 0.815** -0.846** 1 0.764**
Polyps per cm 0.998** 0.539** 0.714** -0.852** 0.764** 1
*Correlation is significant at p < 0.05 **Correlation is significant at p < 0.01
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Fig. 4 Scatter plot with tread lines of total polyps vs. a. Intestine length (R2 = 0.346), b. Intestine %Weight (R2 = 0.484), c. % PCV (R2 = 0.707), d. Spleen
%Weight (R2 = 0.553) and e. Polyps per cm (R2 = 0.995)
Table 3 Mean square between and within groups, and H2 calculations for traits of: total number of polyps, polyp’s distribution in
different parts of intestine (SB1, SB2, SB3) and Colon, intestine length, polyps per cm, intestine %weight, %PCV and spleen %weight
Total polyps SB1 SB2 SB3 Colon Intestine Length Polyps per cm Intestine %Weight %PCV Spleen %Weight
MS between 1874.734 124.804 265.143 241.036 40.197 37.665 0.678 2.992 334.972 1.654
MS within 150.509 12.580 32.091 26.832 10.510 8.471 0.059 0.521 43.910 0.202
H2 0.641 0.581 0.530 0.553 0.305 0.349 0.621 0.424 0.508 0.528
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polyp development. Additionally strong negative correl-
ation was found between the size of spleen and %PCV
values. Therefore, we suggest that the main cause for
splenomegaly is the hemolytic anemia. Several studies
have already showed that erythrocytes trapped in the
spleen cause the enlargement of this organ and increase
anemia [59].
Finally we conclude that modifiers for ApcMin/+ which
affect intestinal tumor development segregate in the CC
population, and that these loci are likely to be mappable
by future QTL analysis. Unfortunately, the number
assessed CC lines in this study (27 lines) were not suffi-
cient and to provide enough statistical power for map-
ping QTL, and it is believed with more lines (additional
20 or so lines) to be assessed in the future, strong and
significant QTL and suggested candidate genes will be
achieved.
Conclusions
Variation in polyp development is controlled, an appre-
ciable extent, by genetic factors segregating in the Col-
laborative cross population and suggests that it is suited
for identifying modifier genes associated with ApcMin/+
mutation, after assessing sufficient number of lines for
quantitative trait loci analysis. The expected findings
may be used for early prediction of potential intestine
cancer development in host carrying susceptible genetic
factors, thus can be applied for better control and suffi-
cient apply therapy tools and approaches.
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